Ngal as a novel target for the treatment of chronic kidney disease

The severity of renal lesions after nephron reduction varied substantially among mouse strains and required activation of EGFR. Lipocalin 2 (Lcn2, also known as neutrophil gelatinase–associated lipocalin [NGAL]), the most highly upregulated gene in a mouse strain which develop severe renal lesions, is not simply a marker of renal lesions, but also an active player in disease progression. The severity of renal lesions was dramatically reduced in Lcn2–/– mice. Lcn2 expression increases upon EGFR activation and Lcn2 mediates its mitogenic effect during renal deterioration. EGFR inhibition prevented Lcn2 upregulation and lesion development in mice expressing a dominant negative EGFR isoform. Cell proliferation was dramatically reduced in Lcn2–/–mice. LCN2 is increased particularly in patients who rapidly progressed to end-stage renal failure. (Viau A. et al., J Clin Invest. 2010 Nov;120(11):4065-76. doi: 10.1172/JCI42004.)

Keywords: Nephrology, Diagnostics, Biomarker, Chronic Kidne
Patent Application number: European Procedure (Patents) (EPA) - 01 Oct. 2010 - 10 306 077.8
BURTIN MartineEL KAROUI KhalilVIAU AmandineNGUYEN Clément
Viau et al 2010 The Journal of Clinical Investiga



    Business Developper
    Aymeric Empereur
    Business Developer
    Patent filling date: 01-10-2010
    Rare disease: No
    Second indication: No

    You might also be interested in